These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 23643624

  • 1. Everolimus immunosuppression in de novo heart transplant recipients: what does the evidence tell us now?
    Zuckermann A, Wang SS, Epailly E, Barten MJ, Sigurdardottir V, Segovia J, Varnous S, Turazza FM, Potena L, Lehmkuhl HB.
    Transplant Rev (Orlando); 2013 Jul; 27(3):76-84. PubMed ID: 23643624
    [Abstract] [Full Text] [Related]

  • 2. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
    Lehmkuhl H, Hetzer R.
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
    [Abstract] [Full Text] [Related]

  • 3. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
    Zuckermann A.
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S206-9; discussion S210-1. PubMed ID: 15774324
    [Abstract] [Full Text] [Related]

  • 4. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors.
    Eisen H, Kobashigawa J, Starling RC, Valantine H, Mancini D.
    Transplant Proc; 2005 May; 37(4 Suppl):4S-17S. PubMed ID: 15809102
    [Abstract] [Full Text] [Related]

  • 5. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation.
    Eisen H.
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii9-13. PubMed ID: 16815858
    [Abstract] [Full Text] [Related]

  • 6. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
    Valantine H, Zuckermann A.
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
    [Abstract] [Full Text] [Related]

  • 7. The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial.
    Arora S, Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Bøtker HE, Rådegran G, Gude E, Ioanes D, Solbu D, Sigurdardottir V, Dellgren G, Erikstad I, Solberg OG, Ueland T, Aukrust P, Gullestad L, SCHEDULE (SCandinavian HEart transplant everolimus De novo stUdy with earLy calcineurin inhibitors avoidancE) Investigators.
    Am J Transplant; 2015 Jul; 15(7):1967-75. PubMed ID: 25783974
    [Abstract] [Full Text] [Related]

  • 8. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H, Ross H.
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [Abstract] [Full Text] [Related]

  • 9. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
    Arora S, Andreassen AK, Karason K, Gustafsson F, Eiskjær H, Bøtker HE, Rådegran G, Gude E, Ioanes D, Solbu D, Dellgren G, Ueland T, Aukrust P, Gullestad L, SCHEDULE (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) Investigators.
    Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
    [Abstract] [Full Text] [Related]

  • 10. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.
    Arora S, Ueland T, Wennerblom B, Sigurdadottir V, Eiskjær H, Bøtker HE, Ekmehag B, Jansson K, Mortensen SA, Saunamaki K, Simonsen S, Gude E, Bendz B, Solbu D, Aukrust P, Gullestad L.
    Transplantation; 2011 Jul 27; 92(2):235-43. PubMed ID: 21677600
    [Abstract] [Full Text] [Related]

  • 11. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH.
    Transplantation; 2010 Apr 15; 89(7):864-72. PubMed ID: 20061999
    [Abstract] [Full Text] [Related]

  • 12. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.
    Kobashigawa J, Ross H, Bara C, Delgado JF, Dengler T, Lehmkuhl HB, Wang SS, Dong G, Witte S, Junge G, Potena L.
    Transpl Infect Dis; 2013 Apr 15; 15(2):150-62. PubMed ID: 23013440
    [Abstract] [Full Text] [Related]

  • 13. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
    Kobashigawa JA, Pauly DF, Starling RC, Eisen H, Ross H, Wang SS, Cantin B, Hill JA, Lopez P, Dong G, Nicholls SJ, A2310 IVUS Substudy Investigators.
    JACC Heart Fail; 2013 Oct 15; 1(5):389-99. PubMed ID: 24621971
    [Abstract] [Full Text] [Related]

  • 14. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
    Fine NM, Kushwaha SS.
    Transplantation; 2016 Dec 15; 100(12):2558-2568. PubMed ID: 27495747
    [Abstract] [Full Text] [Related]

  • 15. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.
    Nashan B.
    Clin Transplant; 2013 Dec 15; 27 Suppl 25():16-29. PubMed ID: 23909498
    [Abstract] [Full Text] [Related]

  • 16. Everolimus in clinical practice--renal transplantation.
    Pascual J.
    Nephrol Dial Transplant; 2006 Jul 15; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.
    Dantal J, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Quéré S, Di Giambattista F, Cassuto E, RAD A2420 Study Group.
    Transpl Int; 2010 Nov 15; 23(11):1084-93. PubMed ID: 20500493
    [Abstract] [Full Text] [Related]

  • 18. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial.
    Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E, Jansson K, Solbu D, Sigurdardottir V, Arora S, Dellgren G, Gullestad L, SCHEDULE Investigators.
    Am J Transplant; 2014 Aug 15; 14(8):1828-38. PubMed ID: 25041227
    [Abstract] [Full Text] [Related]

  • 19. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.
    Viganò M, Tuzcu M, Benza R, Boissonnat P, Haverich A, Hill J, Laufer G, Love R, Parameshwar J, Pulpón LA, Renlund D, Abeywickrama K, Cretin N, Starling RC, Eisen HJ, RAD B253 Study Group.
    J Heart Lung Transplant; 2007 Jun 15; 26(6):584-92. PubMed ID: 17543781
    [Abstract] [Full Text] [Related]

  • 20. Everolimus immunosuppression for renal protection, reduction of allograft vasculopathy and prevention of allograft rejection in de-novo heart transplant recipients: could we have it all?
    Gude E, Gullestad L, Andreassen AK.
    Curr Opin Organ Transplant; 2017 Jun 15; 22(3):198-206. PubMed ID: 28463861
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.